- FDA approves the second Enbrel® (etanercept) biosimilar—no etanercept biosimilar has launched in the United States to date.
- FDA approves the fourth Herceptin® (trastuzumab) biosimilar—no trastuzumab biosimilar has launched in the United States to date.
- European Medicines Agency approves ninth and tenth adalimumab biosimilars and second bevacizumab biosimilar.
As pharmaceutical drug costs attract increasing media attention